Navigation Links
NanoBio Receives SBIR Grant For Genital Herpes Vaccine
Date:3/6/2017

ANN ARBOR, Mich., March 6, 2017 /PRNewswire/ -- NanoBio Corporation today announced that it has been awarded a two-year Phase II Small Business Research Innovation (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of an intranasal nanoemulsion (NE) adjuvanted vaccine for the prevention of genital herpes. The grant will fund up to $1.5 million of critical preclinical research and process development activities, including the completion of a pre-IND meeting with the U.S. Food and Drug Administration.

Genital herpes is a sexually transmitted disease most commonly caused by the herpes simplex virus-2 (HSV-2). Infections are lifelong and are often asymptomatic facilitating the spread of the disease amongst sexual partners and from mother to child during birth. Genital herpes is also associated with an increased risk of HIV acquisition. The disease is widespread in both developed and underdeveloped countries, and is a global health priority. According to estimates from the Centers for Disease Control and Prevention (CDC), over 24 million people in the United States are infected with HSV-2 and there are 776,000 new infections each year. Approximately one out of every six people aged 14 to 49 years has an HSV-2 infection. Currently, there are no approved vaccines to prevent or treat the disease.

Under NIAID's suite of preclinical services, researchers at the Cincinnati Children's Hospital Medical Center previously tested NanoBio's intranasal vaccine in several guinea pig challenge studies. "NanoBio's intranasal vaccine is one of the only vaccine candidates we've studied that has shown efficacy in both the prophylactic and the therapeutic animal models," said Dr. David I. Bernstein, Professor of Pediatrics at Cincinnati Children's Hospital Medical Center. "Based on our data with this unique approach, we look forward to seeing the intranasal NE vaccine progress to human clinical studies."

In the prophylactic guinea pig study, the intranasal NE HSV-2 vaccine prevented infection and viral latency in 92 percent of animals vaccinated, versus 8 percent in a no treatment arm. In a separate therapeutic study, animals with recurrent HSV-2 infection were vaccinated with the intranasal NE vaccine. During the post-vaccination observation period, the NE HSV2 vaccine reduced recurrent lesions and viral shedding by more than 50 percent as compared to animals that received no treatment. No adverse events were observed in any of the animals that received the NE vaccine.

"The Phase II SBIR grant is a testament to the potential of NanoBio's intranasal NE vaccine for genital herpes. The funding enables the next step in the development research process," said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. "Throughout the past several years, we have consistently observed that our intranasal vaccine elicits both a serum and a mucosal immune response in animals. This differentiates our program from the many intramuscular HSV-2 vaccines in development. NanoBio's intranasal NE vaccine provides protection both systemically and in mucosal tissues at the port of entry for the herpes virus. Based on pre-clinical data to date, we believe this first line of defense is essential to adequately protect against genital herpes."

About NanoBio
Headquartered in Ann Arbor, Michigan, NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company's NanoStat® vaccine technology employs a novel oil-in-water nanoemulsion (NE) that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal or intramuscular vaccination. When applied intranasally, NE vaccines elicit both mucosal and systemic immunity.

NanoBio is currently developing NE vaccines for several respiratory and sexually transmitted diseases, including RSV, pertussis, pandemic influenza, anthrax, prophylactic and therapeutic HSV-2, and chlamydia.

For more information on NanoBio or its products, please visit www.nanobio.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanobio-receives-sbir-grant-for-genital-herpes-vaccine-300418367.html


'/>"/>
SOURCE NanoBio Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
2. NanoBio Awarded Up To $10 Million In NIH Funding To Develop A Pandemic Influenza Vaccine
3. Florida Institute Funds Tampa-based TransGenex Nanobiotech, Inc.
4. NanoBios Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
5. Global Nanobiotechnology Applications, Markets and Companies Report 2017-2020 & 2025: Profiles of 250+ Companies with Their 180 Collaborations - Research and Markets
6. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
7. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
8. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
9. Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System
10. BioElectronics Receives Working Capital Infusion
11. Inostics Blood-based Mutation Testing Receives CLIA Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. ... presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which ... Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand has ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... edition of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting ... resources available for individuals with hearing impairments and shares the latest innovations in ...
(Date:8/18/2017)... , ... August 18, 2017 , ... The Dawn Johnson ... inaugurating a new charity drive to generate community support for efforts to educate the ... cures and treatments for all types of cancer. , Each day in America, ...
(Date:8/18/2017)... ... 2017 , ... MLM Insurance Group, a Miami area provider ... is working to support the Take Stock In Children Foundation during a regional ... The Take Stock In Children Foundation (TSC) offers guidance and assistance to low ...
Breaking Medicine News(10 mins):